Eli Lilly (LLY) Aktienübersicht
Eli Lilly and Company erforscht, entwickelt, produziert und vermarktet humanpharmazeutische Produkte in den Vereinigten Staaten, Europa, China, Japan und weltweit. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 1/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 4/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
LLY Community Fair Values
Create NarrativeSee what 734 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Eli Lilly and Company Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$1,208.12 |
| 52-Wochen-Hoch | US$1,215.76 |
| 52-Wochen-Tief | US$623.78 |
| Beta | 0.52 |
| 1 Monat Veränderung | 9.33% |
| 3 Monate Veränderung | 36.26% |
| 1 Jahr Veränderung | 55.80% |
| 3 Jahre Veränderung | 157.61% |
| 5 Jahre Veränderung | 416.38% |
| Veränderung seit IPO | 42,915.12% |
Aktuelle Nachrichten und Updates
Seeking Alpha • Jun 26
Eli Lilly: Exceptional Pipeline, Less Attractive Entry Point (Rating Downgrade)
Summary Eli Lilly and Company ends the first half of 2026 on a high note. Today, LLY stock reached a 52-week high of $1,207.59. Key drivers behind Eli Lilly's recent rally are the unprecedented efficacy of retatrutide in treating people with severe obesity, as well as the strong performance of Mounjaro and Kisunla. So, in the first quarter, LLY sales of Kisunla, its Alzheimer's medication, were $124 million, up 490.5% year-over-year. However, due to sluggish demand for Omvoh, coupled with LLY stock trading at a non-GAAP P/E ratio [FWD] of 31.1x, I'm downgrading its rating to Hold. Read the full article on Seeking Alpha
Narrativ-Update • Jun 24
LLY: Retatrutide Efficacy And GLP-1 Demand Will Support Balanced Outlook
Analysts have nudged up Eli Lilly's fair value estimate by about $4 to $1,218.72, reflecting modestly higher modeled revenue growth and a slightly richer future P/E multiple, supported by recent price target increases tied to retatrutide data and broader GLP-1 expectations. Analyst Commentary Recent commentary on Eli Lilly centers on how retatrutide data and GLP-1 demand expectations filter into valuation, growth assumptions, and execution risk.Recent updates
Seeking Alpha • Jun 26
Eli Lilly: Exceptional Pipeline, Less Attractive Entry Point (Rating Downgrade)
Summary Eli Lilly and Company ends the first half of 2026 on a high note. Today, LLY stock reached a 52-week high of $1,207.59. Key drivers behind Eli Lilly's recent rally are the unprecedented efficacy of retatrutide in treating people with severe obesity, as well as the strong performance of Mounjaro and Kisunla. So, in the first quarter, LLY sales of Kisunla, its Alzheimer's medication, were $124 million, up 490.5% year-over-year. However, due to sluggish demand for Omvoh, coupled with LLY stock trading at a non-GAAP P/E ratio [FWD] of 31.1x, I'm downgrading its rating to Hold. Read the full article on Seeking AlphaNarrativ-Update • Jun 24
LLY: Retatrutide Efficacy And GLP-1 Demand Will Support Balanced Outlook
Analysts have nudged up Eli Lilly's fair value estimate by about $4 to $1,218.72, reflecting modestly higher modeled revenue growth and a slightly richer future P/E multiple, supported by recent price target increases tied to retatrutide data and broader GLP-1 expectations. Analyst Commentary Recent commentary on Eli Lilly centers on how retatrutide data and GLP-1 demand expectations filter into valuation, growth assumptions, and execution risk.Narrativ-Update • Jun 09
LLY: GLP-1 Leadership And Retatrutide Data Will Support Balanced Long-Term Outlook
Analysts have inched up their price targets on Eli Lilly, with several moving into the $1,250 to $1,350 range. They cite full Phase 3 retatrutide data that showed strong obesity and Type 2 diabetes outcomes, with what they view as manageable safety trade offs and a GLP-1 profile they say will be hard for rivals to match.Narrativ-Update • May 26
LLY: GLP-1 Obesity Franchise Leadership Will Drive Long-Term Profitability
Analysts have nudged their price targets on Eli Lilly higher, with our fair value estimate moving by about $2 to $1,211 per share as they factor in expectations for stronger long-term profitability and GLP-1 leadership following positive retatrutide Phase 3 data, partly offset by more tempered revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent research on Eli Lilly clusters around the same theme, retatrutide Phase 3 data supporting a premium valuation for the GLP-1 franchise, but with growing debate over how much future growth is already reflected in the stock.
Narrativ-Update • May 07
LLY: Obesity Pricing Pressure And Safety Headlines Will Shape Future Franchise Economics
Analysts have raised Eli Lilly's implied fair value from $883.99 to $899.73 after several firms increased their price targets by $1 to $50, citing confidence in the obesity and diabetes pipeline, Foundayo's regulatory progress, and clarifications around recent safety concerns. Analyst Commentary Recent research on Eli Lilly reflects a mix of enthusiasm around obesity and diabetes assets and a clearer, more cautious minority that is focused on how much optimism is already reflected in the stock.
Narrativ-Update • Apr 20
LLY: Obesity And Diabetes Platform Will Support Premium Positioning Beyond 2030
Analysts have slightly raised their average price targets on Eli Lilly in recent weeks, citing supportive trial updates in obesity and diabetes, favorable comparisons to competing GLP-1 therapies, and regulatory progress that they say supports high but unchanged fair value estimates of around $1,500. Analyst Commentary Recent Street research around Eli Lilly has been active, with a cluster of price target moves, rating changes, and product specific notes that give you a clearer sense of how professionals are framing the risk and reward.Narrativ-Update • Apr 06
LLY: Oral GLP-1 Launch And Capacity Expansion Will Drive Future Obesity Upside
Analysts have nudged Eli Lilly's price target slightly higher by $1, reflecting updated views on obesity and diabetes franchises following recent Foundayo approval commentary and comparative GLP-1 data. Analyst Commentary Recent research on Eli Lilly clusters around obesity and diabetes, pricing dynamics in GLP-1 therapies, and the implications of new product approvals and trial readouts for long term growth and valuation.
Neues Narrativ • Mar 25
Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth
Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet. WHERE THE STOCK SITS TODAY The current price is around $907 (25/03/2026).Narrativ-Update • Mar 23
LLY: Obesity And Diabetes Franchise Strength Will Support Premium Positioning
Analysts have raised their price target for Eli Lilly to $1,500, citing updated models that reflect slightly stronger assumed revenue growth, a marginally higher profit margin profile, and continued confidence in the obesity and diabetes franchises following recent trial data and supportive sell side research. Analyst Commentary Recent research highlights a split view on Eli Lilly, with some bullish analysts leaning into the obesity and diabetes opportunity set, while at least one more cautious voice questions how much growth is already reflected in the share price.Narrativ-Update • Mar 09
LLY: Obesity Drug Leadership And Pipeline Catalysts Will Sustain Premium Positioning
The updated analyst price target for Eli Lilly has increased to $1,490.52 from $1,429.89. Analysts highlight the obesity and GLP-1 franchise, premium valuations tied to weight loss leadership, and potential upside from pipeline and acquisition catalysts as key factors supporting this change.Narrativ-Update • Feb 23
LLY: GLP-1 Obesity Leadership Will Drive Future Cardiometabolic And M&A Upside
Eli Lilly's analyst price targets have shifted higher, with our fair value estimate moving from $1,093.22 to $1,211.21, as analysts point to sustained GLP-1 obesity leadership, premium valuation support, and an expanding cardiometabolic pipeline as key drivers of their updated views. Analyst Commentary Recent Street research on Eli Lilly clusters around a few clear themes, with bullish analysts focusing on obesity leadership, cardiometabolic breadth, and M&A, while more cautious voices watch valuation and execution risk around the pipeline.Narrativ-Update • Feb 08
LLY: Government Pricing Deals Will Compress Obesity Franchise Economics Going Forward
Analysts have raised their fair value estimate for Eli Lilly from US$770 to about US$884 per share, reflecting updated assumptions on long term obesity opportunities, recent price target increases across several firms, and steady expectations around margins and future P/E multiples. Analyst Commentary The latest batch of research on Eli Lilly revolves around its weight loss and cardiometabolic franchises, expectations for new product launches, and the implications of recent policy developments on pricing and access.Analyseartikel • Feb 07
Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think
Investors in Eli Lilly and Company ( NYSE:LLY ) had a good week, as its shares rose 2.0% to close at US$1,058 following...Narrativ-Update • Jan 25
LLY: Government GLP 1 Pricing Deals Will Pressure Obesity Margins
Analysts have nudged their price targets on Eli Lilly slightly higher, citing continued confidence in the obesity and GLP 1 franchise, supportive government pricing agreements, and potential upside from acquisitions and pipeline catalysts, even as some firms fine tune their models and individual targets by low single digit amounts such as Guggenheim's recent US$2 trim. Analyst Commentary Recent research on Eli Lilly has been dominated by optimism around obesity treatments and government pricing agreements, but there is also a pocket of caution that is worth paying attention to if you are thinking about valuation, execution and long term growth risk.Narrativ-Update • Jan 11
LLY: GLP-1 Pricing Deals Will Pressure Obesity Margins Going Forward
Analysts lifted their fair value estimate for Eli Lilly from US$650 to US$770, citing higher assumed profit margins, a slightly higher discount rate, updated expectations for revenue growth and future P/E, and continued Street support related to the obesity franchise, GLP-1 pricing agreements, and pipeline catalysts. Analyst Commentary Recent Street research around Eli Lilly has been dominated by views on obesity drugs, pricing agreements with the U.S. government, and the company’s expanding pipeline.Narrativ-Update • Dec 27
LLY: GLP-1 Pricing Deals And Policy Will Shape Future Obesity Leadership And Risks
Analysts have lifted their fair value estimate for Eli Lilly to approximately $1,093 from about $1,024, reflecting expectations for stronger long term GLP 1 driven revenue growth, expanding profit margins and sustained leadership in the obesity market, supported by recent U.S. reimbursement and pricing deals. Analyst Commentary Street research remains broadly constructive on Eli Lilly, with a series of upward price target revisions and fresh coverage initiations underscoring confidence in the durability of its GLP 1 franchise and broader innovation pipeline.Narrativ-Update • Dec 13
LLY: Government Access Deals Will Drive Durable Obesity And Diabetes Leadership
Analysts have raised their fair value estimate for Eli Lilly shares from approximately $1,170 to about $1,430 per share, reflecting higher expected profitability and sustained leadership in the GLP 1 obesity and diabetes market, supported by recent U.S. government access deals and upcoming launches such as orforglipron. Analyst Commentary Bullish analysts continue to frame Eli Lilly as a core beneficiary of the expanding obesity and diabetes treatment market, with valuation upside tied to both higher GLP 1 penetration and a broadening metabolic pipeline.Narrativ-Update • Nov 29
LLY: Upcoming Price Discounts And Policy Decisions Will Influence Drug Market Leadership And Risks
Eli Lilly's analyst price target has increased by approximately $21 to $1,024. Analysts cite earnings upside, expanding obesity drug opportunities, and recently announced government reimbursement agreements as key drivers of improved growth and profitability expectations.Aktionärsrenditen
| LLY | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 10.0% | 9.1% | -2.5% |
| 1Y | 55.8% | 49.3% | 19.0% |
Rendite im Vergleich zur Industrie: LLY übertraf die Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 49.3 erzielte.
Rendite vs. Markt: LLY übertraf den Markt US, der im vergangenen Jahr eine Rendite von 19 erzielte.
Preisvolatilität
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: LLY hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: LLYDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1876 | 50,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company erforscht, entwickelt, produziert und vermarktet Humanarzneimittel in den Vereinigten Staaten, Europa, China, Japan und weltweit. Das Unternehmen bietet Produkte für die kardiometabolische Gesundheit an, darunter Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, Insulin Lispro, Insulin Lispro Protamin, Insulin Lispro Mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 zur Behandlung von Diabetes; Jardiance, Mounjaro und Trulicity zur Behandlung von Typ-2-Diabetes; sowie Zepbound zur Behandlung von Adipositas. Darüber hinaus bietet das Unternehmen onkologische Produkte an, darunter Cyramza zur Zweitlinienbehandlung von Magenkrebs oder Adenokarzinomen im gastroösophagealen Übergang; Erbitux bei kolorektalen Karzinomen und Kopf-Hals-Karzinomen; Inluriyo bei Brustkrebs; Jaypirca bei chronischer lymphatischer Leukämie oder kleinzytischem Lymphom; Retevmo zur Behandlung von metastasiertem nicht-kleinzelligem Lungenkrebs (NSCLC); TYVYT bei klassischem Hodgkin-Lymphom; sowie Verzenio bei Brustkrebs.
Eli Lilly and Company's Grundlagenzusammenfassung
| LLY grundlegende Statistiken | |
|---|---|
| Marktanteil | US$1.08t |
| Gewinn(TTM) | US$25.28b |
| Umsatz(TTM) | US$72.25b |
42.6x
Kurs-Gewinn-Verhältnis 14.9x
Kurs-Umsatz-VerhältnisIst LLY zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| LLY Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$72.25b |
| Kosten der Einnahmen | US$12.40b |
| Bruttogewinn | US$59.85b |
| Sonstige Ausgaben | US$34.57b |
| Gewinn | US$25.28b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Aug 05, 2026
| Gewinn per Aktie (EPS) | 28.35 |
| Bruttomarge | 82.83% |
| Nettogewinnspanne | 34.99% |
| Schulden/Eigenkapital-Verhältnis | 139.0% |
Wie hat sich LLY auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.6%
Aktuelle Dividendenrendite22%
AusschüttungsquoteZahlt LLY eine zuverlässige Dividende?
Siehe LLY Dividendenhistorie und Benchmarks| Eli Lilly Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Aug 14 2026 |
| Datum der Dividendenzahlung | Sep 10 2026 |
| Tage bis Ex-Dividende | 46 days |
| Tage bis zum Datum der Dividendenzahlung | 73 days |
Zahlt LLY eine zuverlässige Dividende?
Siehe LLY Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/28 19:20 |
| Aktienkurs zum Tagesende | 2026/06/26 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Eli Lilly and Company wird von 52 Analysten beobachtet. 28 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |